…
Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Translational Development Acquisition Corp. is a Nasdaq-listed special purpose acquisition company with limited operating history whose principal activity is sourcing and completing a business combination. Long-term prospects hinge on the performance of any merged target; investors may find appeal in pre-merger exposure to emerging healthcare or biotech assets and potential upside from a successful combination.
Key risks are deal execution and dilution typical of SPACs, clinical and regulatory uncertainty if the target is life-sciences, financing and market-timing uncertainty, and possible liquidation if no qualifying merger occurs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Income before tax | 6.36M | -0.07M | -0.49M | -0.07M |
| Net income | 6.36M | -0.07M | -0.49M | -0.07M |
| Selling general administrative | 0.94M | 9125.38M | 0.49M | 0.07M |
| Gross profit | - | 744.92M | - | - |
| Ebit | - | - | -0.49M | -0.07M |
| Ebitda | -0.94M | -0.07M | -0.49M | - |
| Depreciation and amortization | - | - | - | 0.07M |
| Operating income | -0.94M | -0.20M | -0.49M | -0.07M |
| Other operating expenses | 0.94M | 0.20M | 0.49M | 0.07M |
| Interest expense | - | 508.56M | - | - |
| Total revenue | 0.00M | 0.00M | 0.00M | - |
| Total operating expenses | 0.94M | 0.20M | 0.49M | 0.07M |
| Cost of revenue | - | 320.87M | - | - |
| Total other income expense net | 7.31M | 0.13M | -0.49M | - |
| Net income from continuing ops | 6.36M | - | -0.49M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Total assets | 181.70M | 175.00M | 0.00M | 0.44M |
| Intangible assets | - | 12569165.00M | - | - |
| Other current assets | 0.01M | 0.21M | - | 0.05M |
| Total liab | 6.58M | 6.25M | 0.51M | 0.46M |
| Total stockholder equity | 175.12M | 168.75M | -0.51M | -0.02M |
| Other current liab | 0.18M | -6110776.81M | 0.16M | 0.40M |
| Common stock | 181.66M | 18327.00M | 0.00M | 0.00M |
| Capital stock | 181.66M | 174.35M | 0.00M | 0.00M |
| Retained earnings | -6.54M | -5.60M | -0.53M | -0.05M |
| Good will | - | 9061675.00M | - | - |
| Cash | 0.03M | 0.44M | 0.00M | 0.00M |
| Total current liabilities | 0.54M | 0.21M | 0.51M | 0.46M |
| Net debt | 0.17M | -0.44M | 0.35M | 0.26M |
| Short term debt | 0.20M | 6110777.00M | 0.35M | 0.26M |
| Short long term debt | 0.20M | - | 0.35M | 0.26M |
| Short long term debt total | 0.20M | 6110777.00M | 0.35M | 0.26M |
| Other stockholder equity | - | -35032.65M | 0.02M | 0.02M |
| Total current assets | 0.04M | 0.65M | 0.00M | 0.05M |
| Accounts payable | 0.16M | 0.02M | 0.00M | - |
| Accumulated other comprehensive income | - | 16880.00M | - | - |
| Non currrent assets other | 181.66M | -21630840.00M | - | 0.38M |
| Non current assets total | 181.66M | 174.35M | 0.00M | 0.38M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Investments | - | -174.22M | 0.00M | - |
| Total cashflows from investing activities | - | -174.22M | - | - |
| Net borrowings | 0.20M | -0.39M | 0.00M | - |
| Total cash from financing activities | 0.20M | 175.51M | 0.00M | 0.10M |
| Net income | 6.36M | -0.07M | -0.49M | -0.00M |
| Change in cash | -0.41M | 0.44M | -0.00M | 0.00M |
| Begin period cash flow | 0.44M | 0.00M | 0.00M | - |
| End period cash flow | 0.03M | 0.44M | 0.00M | 0.00M |
| Total cash from operating activities | -0.61M | -0.85M | -0.00M | -0.10M |
| Issuance of capital stock | 0.00M | 169.05M | 0.00M | - |
| Other cashflows from investing activities | - | -174.22M | - | - |
| Dividends paid | 7.31M | 0.13M | - | - |
| Other cashflows from financing activities | 7.31M | 6.98M | - | 0.00M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.34M | -0.66M | 0.00M | -0.00M |
| Other non cash items | -7.31M | -0.12M | 0.48M | -0.10M |
| Free cash flow | -0.61M | -0.85M | -0.00M | -0.00M |
Sector: Financial Services Industry: Shell Companies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| TDAC Translational Development Acquisition Corp. Ordinary Shares |
0.00 0.05% |
10.87 | 41.92 | - | - | 1.40 |
| CLUS CLUS |
- -% |
200.00 | - | - | 0.09 | 0.92 |
| SGDH Sgd Holdings Ltd |
-0.89 88.82% |
0.11 | - | - | 59741.55 | 0.56 |
| LION Lionsgate Studios Holding Corp. |
1.66 13.22% |
14.22 | - | 23.31 | 1.13 | 1.35 |
| QKIE QKIE |
- -% |
1.88 | - | - | 470.20 | - |
Translational Development Acquisition Corp. does not have significant operations. The company intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Translational Development Acquisition Corp. was incorporated in 2022 and is based in New York, New York.
52 E. 83rd Street, New York, NY, United States, 10028
917 979 3072
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael M. B. Hoffman J.D. | Chairman of the Board & CEO | 1950 |
| Mr. Avi C. Das | Chief Financial Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.